These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 32173689)

  • 1. A Healthy Family of Familial Hypobetalipoproteinemia Caused by a Protein-truncating Variant in the PCSK9 Gene.
    Tada H; Okada H; Nomura A; Nohara A; Takamura M; Kawashiri MA
    Intern Med; 2020; 59(6):783-787. PubMed ID: 32173689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Familial hypobetalipoproteinemia caused by homozygous loss-of-function mutations in PCSK9: A case report.
    Kudo T; Sasaki K; Tada H
    J Clin Lipidol; 2022; 16(5):596-600. PubMed ID: 35931648
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PCSK9 dominant negative mutant results in increased LDL catabolic rate and familial hypobetalipoproteinemia.
    Cariou B; Ouguerram K; Zaïr Y; Guerois R; Langhi C; Kourimate S; Benoit I; Le May C; Gayet C; Belabbas K; Dufernez F; Chétiveaux M; Tarugi P; Krempf M; Benlian P; Costet P
    Arterioscler Thromb Vasc Biol; 2009 Dec; 29(12):2191-7. PubMed ID: 19762784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Family with Familial Hypobetalipoproteinemia Caused by a c.1468C>T in APOB.
    Tada H; Kojima N; Nomura A; Takamura M
    Intern Med; 2024 Feb; ():. PubMed ID: 38369355
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The c.43_44insCTG variation in PCSK9 is associated with low plasma LDL-cholesterol in a Caucasian population.
    Yue P; Averna M; Lin X; Schonfeld G
    Hum Mutat; 2006 May; 27(5):460-6. PubMed ID: 16619215
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel loss of function mutation of PCSK9 gene in white subjects with low-plasma low-density lipoprotein cholesterol.
    Fasano T; Cefalù AB; Di Leo E; Noto D; Pollaccia D; Bocchi L; Valenti V; Bonardi R; Guardamagna O; Averna M; Tarugi P
    Arterioscler Thromb Vasc Biol; 2007 Mar; 27(3):677-81. PubMed ID: 17170371
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel APOB mutations by targeted next-generation sequencing for the molecular diagnosis of familial hypobetalipoproteinemia.
    Rimbert A; Pichelin M; Lecointe S; Marrec M; Le Scouarnec S; Barrak E; Croyal M; Krempf M; Le Marec H; Redon R; Schott JJ; Magré J; Cariou B
    Atherosclerosis; 2016 Jul; 250():52-6. PubMed ID: 27179706
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phenotypic Differences Between Polygenic and Monogenic Hypobetalipoproteinemia.
    Rimbert A; Vanhoye X; Coulibaly D; Marrec M; Pichelin M; Charrière S; Peretti N; Valéro R; Wargny M; Carrié A; Lindenbaum P; Deleuze JF; Genin E; Redon R; Rollat-Farnier PA; Goxe D; Degraef G; Marmontel O; Divry E; Bigot-Corbel E; Moulin P; Cariou B; Di Filippo M
    Arterioscler Thromb Vasc Biol; 2021 Jan; 41(1):e63-e71. PubMed ID: 33207932
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case of hypocholesterolemia under study.
    Camacho A; Ariza MJ; Amigó N; Macías Guillén P; Sánchez Chaparro MÁ; Valdivielso P
    Clin Investig Arterioscler; 2023; 35(5):244-247. PubMed ID: 37302939
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Familial hypobetalipoproteinemia in a hospital survey: genetics, metabolism and non-alcoholic fatty liver disease.
    Gutiérrez-Cirlos C; Ordóñez-Sánchez ML; Tusié-Luna MT; Patterson BW; Schonfeld G; Aguilar-Salinas CA
    Ann Hepatol; 2011; 10(2):155-64. PubMed ID: 21502677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HIV and Hepatitis C-Coinfected Patients Have Lower Low-Density Lipoprotein Cholesterol Despite Higher Proprotein Convertase Subtilisin Kexin 9 (PCSK9): An Apparent "PCSK9-Lipid Paradox".
    Kohli P; Ganz P; Ma Y; Scherzer R; Hur S; Weigel B; Grunfeld C; Deeks S; Wasserman S; Scott R; Hsue PY
    J Am Heart Assoc; 2016 Apr; 5(5):. PubMed ID: 27130349
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors: Present perspectives and future horizons.
    Yadav K; Sharma M; Ferdinand KC
    Nutr Metab Cardiovasc Dis; 2016 Oct; 26(10):853-62. PubMed ID: 27352986
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low levels of low-density lipoprotein-C associated with proprotein convertase subtilisin kexin 9 inhibition do not increase the risk of hemorrhagic transformation.
    Tran-Dinh A; Levoye A; Lambert G; Louedec L; Journé C; Meilhac O; Amarenco P
    Stroke; 2014 Oct; 45(10):3086-8. PubMed ID: 25123222
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum proprotein convertase subtilisin/kexin type 9 concentration is not increased by plant stanol ester consumption in normo- to moderately hypercholesterolaemic non-obese subjects. The BLOOD FLOW intervention study.
    Simonen P; Stenman UH; Gylling H
    Clin Sci (Lond); 2015 Sep; 129(5):439-46. PubMed ID: 25857271
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between familial hypobetalipoproteinemia and the risk of diabetes. Is this the other side of the cholesterol-diabetes connection? A systematic review of literature.
    Noto D; Arca M; Tarugi P; Cefalù AB; Barbagallo CM; Averna MR
    Acta Diabetol; 2017 Feb; 54(2):111-122. PubMed ID: 27804036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Rare and common variants of APOB and PCSK9 in Korean patients with extremely low low-density lipoprotein-cholesterol levels.
    Lee CJ; Lee Y; Park S; Kang SM; Jang Y; Lee JH; Lee SH
    PLoS One; 2017; 12(10):e0186446. PubMed ID: 29036232
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease.
    Welty FK
    Curr Opin Lipidol; 2020 Apr; 31(2):49-55. PubMed ID: 32039990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
    Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
    J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apolipoprotein(a) phenotype determines the correlations of lipoprotein(a) and proprotein convertase subtilisin/kexin type 9 levels in patients with potential familial hypercholesterolemia.
    Afanasieva OI; Ezhov MV; Razova OA; Afanasieva MI; Utkina EA; Pokrovsky SN
    Atherosclerosis; 2018 Oct; 277():477-482. PubMed ID: 30270088
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum levels of proprotein convertase subtilisin/kexin type 9 in subjects with familial hypercholesterolemia indicate that proprotein convertase subtilisin/kexin type 9 is cleared from plasma by low-density lipoprotein receptor-independent pathways.
    Cameron J; Bogsrud MP; Tveten K; Strøm TB; Holven K; Berge KE; Leren TP
    Transl Res; 2012 Aug; 160(2):125-30. PubMed ID: 22683370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.